Target species
Horses.
Indications for use for each target species
For the active immunisation of horses of 5 months of age or older against tetanus to prevent mortality.
Onset of immunity: within 2 weeks of completion of the primary course.
Duration of immunity: 3 years.
Contraindications
None.
Special warnings
Vaccinate healthy animals only.
Special precautions for use
Special precautions for safe use in the target species:
The efficacy of active immunisation of young foals against equine influenza will be influenced by the level of maternally derived antibodies. This will vary between individuals due to a number of factors, e.g. the immune status of the dam; adequacy of colostral intake by the foal etc. The vaccine should not be used in foals below 5 months of age, and foals should not be vaccinated until maternally derived antibodies have fallen below protective levels.
In any animal population there may be a small number of individuals which fail to respond fully to vaccination. Successful vaccination depends upon correct storage and administration of the vaccine and the ability of the animal to respond. This can be influenced by such factors as genetic constitution, intercurrent infection, age, nutritional status, concurrent drug therapy and stress.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
The product should be administered by respecting appropriate (aseptic) injection technique.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet of the label to the physician.
Special precautions for the protection of the environment:
Not applicable.
Other precautions:
Not applicable.
Adverse events
Horses.
Rare (1 to 10 animals / 10,000 animals treated): | Injection site swelling1,3 Stiffness1 Elevated temperature1,2 |
Very rare (<1 animal / 10,000 animals treated, including isolated reports): | Injection site pain Hypersensitivity reaction4 |
1 This condition normally resolves by the day following vaccination.
2 Mild, transient, typically 9-12 hours post vaccination.
3 Local, small (10-20 mm in diameter), soft, non-painful.
4 In the event of an allergic reaction or anaphylactic reaction, immediate treatment should be given with a soluble glucocorticoid intravenously or adrenalin intramuscularly.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy, lactation or lay
Pregnancy:
The vaccine may be used in pregnant mares which have been vaccinated against tetanus before pregnancy.
Heavily pregnant mares should not be subject to undue stress when vaccinated.
Interaction with other medicinal products and other forms of interaction
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Administration routes and dosage
Dose: 2 ml.
Administration: Equip T should be shaken thoroughly before use and administered by deep intramuscular injection.
Primary vaccination
Two injections of 2 ml with an interval of 4-6 weeks between them.
Booster vaccination
One dose 36 months after the primary course, repeated at intervals of up to 36 months.
Symptoms of overdose (and where applicable, emergency procedures and antidotes)
Accidental overdosage is unlikely to cause any reactions other than those described in section 3.6.
Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance
Not applicable.
Withdrawal periods
Zero days.